Recurrent Diabetic Macular Edema: What to Do

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Diabetic macular edema (DME) is a significant cause of vision loss in working-aged individuals.
• Recurrent DME poses challenges for long-term management and visual preservation.

Observation:

• A patient with a 6-year history of recurrent DME, refractory to multiple treatments, was studied.
• The patient presented with severe visual impairment (2/10 acuity) and significant macular thickening (488 µm).

Findings:

• A single intravitreal implant of sustained-release fluocinolone acetonide was administered.
• Post-treatment, best-corrected visual acuity improved to 6/10, and central macular thickness reduced to 198 µm.
• Sustained functional and anatomical improvements were observed for over 12 months with a manageable safety profile.

Implications:

• Fluocinolone acetonide intravitreal implantation demonstrates efficacy as a treatment for DME.
• This therapeutic option warrants consideration within established DME treatment algorithms.
• Sustained-release corticosteroid implants offer a potential long-term solution for refractory DME.